Clinical and Population Studies

Identification of Peroxiredoxin-1 as a Novel Biomarker of Abdominal Aortic Aneurysm

Roxana Martinez-Pinna, Priscila Ramos-Mozo, Julio Madrigal-Matute, Luis M. Blanco-Colio, Juan A. Lopez, Enrique Calvo, Emilio Camafeita, Jes S. Lindholt, Olivier Meilhac, Sandrine Delbosc, Jean-Baptiste Michel, Melina Vega de Ceniga, Jesus Egido, Jose L. Martin-Ventura
https://doi.org/10.1161/ATVBAHA.110.214429
Arteriosclerosis, Thrombosis, and Vascular Biology. 2011;31:935-943
Originally published March 16, 2011

Jump to

Abstract

Objective—In the search of novel biomarkers of abdominal aortic aneurysm (AAA) progression, proteins released by intraluminal thrombus (ILT) were analyzed by a differential proteomic approach.

Methods and Results—Different layers (luminal/abluminal) of the ILT of AAA were incubated, and the proteins released were analyzed by 2-dimensional difference in-gel electrophoresis. Several differentially expressed proteins involved in main AAA pathological mechanisms (proteolysis, oxidative stress, and thrombosis) were identified by mass spectrometry. Among the proteins identified, peroxiredoxin-1 (PRX-1) was more released by the luminal layer compared with the abluminal layer of the ILT, which was further validated by Western blot, ELISA, and immunohistochemistry. We demonstrated increased PRX-1 serum levels in AAA patients compared with healthy subjects and also positive correlation among PRX-1 and AAA diameter, plasmin-antiplasmin, and myeloperoxidase levels. Finally, a prospective study revealed a positive correlation between PRX-1 serum levels and AAA expansion rate. Moreover, the combination of PRX-1 and AAA size had significantly additive value in predicting growth.

Conclusion—Several proteins associated with AAA pathogenesis have been identified by a proteomic approach in ILT-conditioned medium. Among them, PRX-1 serum levels are increased in AAA patients and correlate with AAA size and growth rate, suggesting the potential use of PRX-1 as a biomarker for AAA evolution.

Abdominal aortic aneurysm (AAA) is an important health problem, which occurs in up to 9% of adults older than 65 years of age. The incidence of asymptomatic and ruptured AAA has increased during recent decades, causing ≈1% to 2% of male deaths in Western countries.1 Because AAAs are usually asymptomatic before rupture, the present clinical challenges are to diagnose AAA at an early stage and to decipher the biological mechanisms leading to progressive dilatation and finally rupture, to develop new diagnostic and therapeutic approaches. Identification of biomarkers could help to target both objectives.

Previous studies have identified AAA biomarkers by studying the levels of different molecules potentially related to AAA pathological mechanisms.2,3 A different noncandidate biomarker strategy using a set of modern high-throughput technologies, including proteomics, will offer new opportunities to gain a deeper insight into disease processes, including their molecular mechanisms, the risk factors involved, and the analysis of disease progression.4,5 We have previously reported a differential proteomic approach to identify new atherothrombosis biomarkers released by the arterial wall into plasma using normal and pathological arteries in culture.6,7 The presence of an intraluminal thrombus (ILT) is a main feature of AAA, and recent data suggest that the biological activities of ILT play a major role in AAA development in humans.8 In this study, different layers (luminal/abluminal) from the ILT of human AAA patients were incubated in protein-free medium, and the released proteins were analyzed by a gel-based (2-dimensional difference in-gel electrophoresis [2D-DIGE]) proteomic approach followed by protein identification by mass spectrometry (MS). We focused on peroxiredoxin-1 (PRX-1) in view of its potential role in modulating oxidative stress and thus validated its differential expression by Western blot and ELISA in the conditioned medium. Finally, the suitability of PRX-1 as a biomarker of AAA presence and progression was assessed in sera from 2 different population studies by ELISA.

Materials and Methods

AAA Tissue and Tissue-Conditioned Media

Ten human AAA thrombus samples were collected during surgical repair and dissected into luminal and abluminal parts (at the interfaces with circulating blood and with the remaining media, respectively). AAA samples were obtained from patients undergoing surgery, enrolled in the RESAA protocol (Reflet sanguin de l'évolutivité des anévrysmes de l'aorte abdominale; Comités Consultatifs de Protection des Personnes dans la Recherche Biomédicale Paris-Cochin numbers 2095, 1930, and 1931).9 All patients gave their informed written consent, and the protocol was approved by a French ethics committee (Comités Consultatifs de Protection des Personnes dans la Recherche Biomédicale, Cochin Hospital). Luminal and abluminal layers of AAA thrombus were cut into small pieces (5 mm3) and separately incubated in RPMI 1640 medium containing antibiotics and an antimycotic (Gibco) for 24 hours at 37°C (6 mL/g of wet tissue). The conditioned medium (supernatant containing proteins released by the tissue sample) was obtained after centrifugation at 3,000g for 10 minutes at 20°C. The protein concentration of each conditioned medium was measured using the Bradford assay (Bio-Rad).

Sample Preparation and DIGE Protein Labeling

Supernatants from luminal and abluminal layers of ILT human samples from 4 individual patients were isolated, and the proteins were precipitated using the 2D clean-up kit (GE Healthcare) and resuspended in 30 mmol/L Tris-HCl, pH 8.5, 7 mol/L urea, 2 mol/L thiourea, and 40 g/L CHAPS. Protein concentration was measured by RC-DC protein assay kit (Bio-Rad).

The comparison between the proteins released by luminal and abluminal layers was performed by 2D-DIGE analyses across 4 gels, using the same pooled-sample internal standard, the equimolecular mixture of all the samples, in all gels. The samples were labeled according to manufacturer's instructions for minimal labeling, using 400 pmol of dye reagent for 50 μg of protein extract. Individual samples were labeled with Cy3 or Cy5 dyes using dye switching, and the internal standard was always Cy2 labeled. The labeling reaction was performed on ice for 30 minutes in darkness and quenched by 1 μL of lysine (10 mmol/L) for 10 minutes.

2D Electrophoresis and Image Acquisition

The 4-paired samples of Cy3- and Cy5-labeled proteins were mixed with 50 μg of Cy2-labeled internal standard. The mixtures were diluted in rehydration buffer (7 mol/L urea, 2 mol/L thiourea, 40 g/L CHAPS, 0.8% IPG buffer 3-11NL, and bromphenol blue) containing 50 mmol/L immobilized pH gradient and resolved on 24-cm pH 3–11 nonlinear gradient IPG strips (GE Healthcare). The samples were applied by cup loading to the previously rehydrated IPG Strips with 450 μL of the aforementioned rehydration buffer containing 97 mmol/L DeStreak (GE Healthcare).

The isoelectric focusing was carried out in an IPGphor II isoelectric focusing system (GE Healthcare) until a total of 42 kVh was reached. After isoelectric focusing, strips were equilibrated in buffer containing 6 mol/L urea, 400 mmol/L glycerol, 7 mmol/L SDS, and bromphenol blue, for 15 minutes with addition of 6.5 mmol/L dithiothreitol, and then without dithiothreitol but with the same buffer supplemented with 21.6 mmol/L iodoacetamide for an additional 15 minutes. SDS-PAGE was carried out on 12% polyacrylamide gels at 2 W/gel.

The differentially labeled coresolved proteins in each gel were acquired with a Typhoon 9400 laser scanner (GE Healthcare), and Cy2-, Cy3-, and Cy5-labeled images of each gel were acquired at excitation/emission wavelength values of 488/520, 523/580, and 633/670 nm, respectively. Finally, gels were fixed in 12% methanol and 7% acetic acid and silver stained using the Plus One silver staining kit (GE Healthcare).

DIGE Data Analysis

The images were analyzed using the DeCyder version 6.5 software (GE Healthcare) for spot detection and quantification and intergel matching and statistics. DeCyder calculates the average abundance for each spot among the 4 gels under study. Statistical significance was assessed for each change in abundance using the paired Student t test analysis. We considered spots present in all of the 12 images (Cy2-, Cy3-, and Cy5-labeled images of each gel) with statistical significance at 95% confidence level for standardized average spot volume ratios greater than 1.5.

Protein Identification by Matrix-Assisted Laser Desorption Ionization-MS

Differentially expressed spots were selected from silver-stained gels for gel excision, automated digestion,10 and analysis in an Ultraflex matrix-assisted laser desorption ionization (MALDI) time-of-flight/time-of-flight mass spectrometer (Bruker Daltonik) to obtain the corresponding MALDI-MS and MALDI-MS/MS spectra as described.11,12 These MS and MS/MS combined data were used to search a nonredundant protein database (NCBInr; ≈107 entries; National Center for Biotechnology Information, Bethesda, MD) using the Mascot software (Matrix Science).13 Detailed information is included the Supplemental Methods, available online at http://atvb.ahajournals.org.

Western Blot

Equal amounts (50 μg of protein) of conditioned medium were loaded onto 12.5% polyacrylamide gels, electrophoresed, and transferred to nitrocellulose membranes. Then they were blocked with 7% milk powder in TBS-T for 1 hour and incubated overnight at 4°C at 1:500 with anti-peroxiredoxin antibody (Santa Cruz Biotechnology, goat polyclonal sc-23969). Then, the membranes were washed with TBS-T and incubated with anti-goat antibody (1:2000) for 1 hour at room temperature. After 4 washes, the signal was detected using the ECL chemiluminiscence kit (GE Healthcare).

ELISA

The soluble concentration of PRX-1 in both conditioned media and serum was quantified with a commercial kit following the manufacturer's instructions (AbFrontier). The interassay and intraassay variability values were 9% and 6%, respectively.

Immunohistochemistry

AAA thrombus samples were fixed in 3.7% paraformaldehyde and embedded in paraffin. Immunohistochemistry was performed on 5-μm sections, using rabbit anti-peroxiredoxin 1 (ab-15571) at 1:100 overnight at 4°C as the primary antibody. The peroxidase LSAB+ system horseradish peroxidase kit (Dako), followed by Histogreen peroxidase substrate (AbCys SA), was used for detection. Sections were then counterstained with Nuclear Fast Red for 5 minutes at room temperature before being mounted using Eukitt medium. Control irrelevant rabbit immunoglobulins (Dako) were applied at the same concentrations as primary antibodies to assess nonspecific staining.

Red Blood Cell In Vitro Experiments

Blood was collected in EDTA-tubes from 6 healthy volunteers. The blood sample was centrifuged at 2500 rpm for 15 minutes to eliminate plasma, and then blood cells were diluted 1:1 in PBS (154 mmol/L NaCl, 10 mmol/L phosphate buffer, pH 7.4) and were separated by centrifugation in Ficoll-Paque (GE Healthcare). Finally, red blood cells (RBCs) and leukocytes were separated by 6% dextran sedimentation of the pellet. Erythrocytes were incubated with lipopolysaccharide (0.1 and 1 ng/mL) and H2O2 (5 and 500 μmol/L) for 30 minutes. The lysis of RBCs was achieved by hypotonic shock, using repetitive washes with distilled water, and finally by adding NaCl (3.5%). Membrane fractions were collected after centrifugation at 12 000 rpm for 10 minutes.

Hydrogen Peroxide Quantification

Quantitative determination of hydrogen peroxide was performed with a commercial colorimetric kit (907-015, Assay Design) following the manufacturer's instructions.

AAA Patient Sera

Spanish Study

The study was approved by the Spanish center's research and ethics committees, and informed consent from the patients and the controls for their inclusion in the study was obtained. Eighty-three consecutive patients with an asymptomatic infrarenal AAA were recruited, and for each, the AAA size at the time of blood sample collection was registered (Supplemental Table I). We excluded patients with symptomatic or inflammatory AAA, multiple synchronic aneurysms (thoracic, femoral, popliteal), and AAA with a location other than infrarenal. We also excluded patients with active inflammatory or acute infectious processes, surgical procedures or major trauma in the previous 60 days, and chronic antiinflammatory or immunosupressive medication.

Thirty-three controls were recruited from a screening program, which is currently being performed among the population in the area under our care.14 They were randomly selected from the screened individuals with nondilated (<30 mm, confirmed with abdominal ultrasound) infrarenal aortas. Neither patients nor controls showed any significant differences in age, sex, or cardiovascular risk factors.

Viborg Study

In 1994, half (4404) of all 65 to 73 year-old males in Viborg County, Denmark, were invited to B-mode-ultrasonographic screening for AAA at their regional hospital. The trial was approved by the respective local scientific ethics committees and reported to the Danish Central Control of Registers.

An AAA was defined as an infrarenal aortic diameter of 30 mm or more, and AAAs >50 mm were referred for surgery. AAAs of 30 to 49 mm were offered yearly follow-up examinations to check for any expansion.15 Two observers were used, and the arithmetic interobserver variation (2 SD) was 1.4 mm.16

The serum samples were left for coagulation at room temperature for 45 minutes before centrifugation. A random sample of 80 cases was used in this study of peroxiredoxin. Follow-up was truncated after 10 years. Sixteen men were referred to planned AAA repair because of expansion (Supplemental Table II). The expansion rate was calculated as the change in the anteriorposterior diameter during the whole observation period, transformed to annual units. The trial was approved by the respective local scientific ethics committees and reported to the Danish Central Control of Registers.

Statistics

ELISA and Western blot results are expressed as mean±SEM. The Wilcoxon paired test was used to analyze differences in PRX-1 levels between luminal and abluminal supernatants of the same samples. The analysis of small and large AAA and control groups was performed with nonparametric tests (Mann-Whitney U tests). Pearson correlation analysis was used to examine the univariate correlation between PRX-1 and AAA expansion rate, and it was adjusted for current smoking, body mass index, previous cardiovascular events, use of glucocorticoids, low-dose aspirin, β-blockers, angiotensin coverting enzyme inhibitors, and ankle brachial blood pressure index. The receiving-operating characteristic (ROC) curve analysis was performed to test the predictive clinical value of PRX-1 and initial AAA size, univariately and combined in a multivariate linear regression model concerning prediction of cases expanding more than 1.68 mm/year (mean annual growth). For the analysis of the ROC curve, the null hypothesis was that the test had a performance similar to the diagonal line, ie, the area under the curve was 0.5. If the lowest 95% confidence limit for the area under the curve was more than 0.5, a significant predictive test was said to be present.

Results

DIGE Analysis of ILT Supernatants

Because ILT is involved in AAA evolution and ILT material can be sampled during surgery, it represents a highly relevant model for the study of biological events participating in human AAA. We hypothesized that the proteins differentially released by the biologically active luminal part of the ILT versus the abluminal layer may reflect ILT activity. Proteins released from these different layers (luminal/abluminal) of the ILT of AAA were analyzed by a noncandidate based proteomic strategy using 2D-DIGE (Figure 1). DeCyder analysis revealed 42 differentially expressed spots, and after silver staining of the gels, only visible spots were excised, digested with trypsin, and subjected to MS-based protein identification. Thirty-two proteins out of the 42 spots released differently by the luminal layer compared with the abluminal layer were finally identified by MS (Table and Supplemental Figure I); these proteins are involved in different AAA pathological mechanisms, such as redox balance (eg, peroxiredoxin), inflammatory processes (eg, complement components), extracellular matrix remodeling (thrombospondin), hemostasis (eg, fibrinogen), or heme-related proteins (eg, hemopexin).

Figure 1.
Figure 1.

DIGE of AAA-conditioned media. Luminal and abluminal layers from ILT of 4 AAA patients were incubated in protein-free medium. Secreted proteins were labeled with the corresponding CyDye reagents, mixed, resolved on 4 independent DIGE gels, and imaged (red, Cy3; green, Cy5; blue, Cy2) and analyzed with DeCyder software. A, A representative gel image from the 3-plex DIGE experiment is shown. Proteins were resolved in the 3 to 11 (nonlinear) pH range in the first dimension and on 12% polyacrylamide gels in the second dimension. B, Spots showing statistically significant regulation between the 2 conditions were excised from silver-stained gels and identified by MALDI-MS. Identified spots are numbered as listed in the Table.

View this table:
Table.

Proteins Differentially Released From Different Layer Regions (Luminal/Abluminal) of the ILT of Human AAA as Revealed by 2D-DIGE and Identified by MALDI-MS

PRX-1 Is Mainly Localized and Released by the Luminal Part of AAA Thrombus

Among the differential proteins identified by 2D-DIGE and MS that were found to be altered in the 4 patients and not previously related to AAA, we focused on PRX-1 because regulation of oxidative stress is of major importance in AAA pathophysiology. We validated the levels of PRX-1 in the conditioned media from the same samples used in the DIGE experiment (n=4) and from an additional group of human AAA samples (n=6). PRX-1 release was increased in the luminal layer of the ILT of AAA compared with the abluminal layer, as assessed by ELISA (32±10 versus 10±2 ng/mL, P<0.05) and Western blot (Figure 2). Immunodetection of PRX-1 in AAA thrombus (Figure 2D) showed a strong staining in the luminal layer mainly associated with RBCs and polymorphonuclear neutrophils.17 Both cellular and diffuse staining was observed, which suggests a potential release of PRX-1 in the extracellular compartment. On the contrary, the abluminal layer exhibited a faint staining, in accordance with results obtained by 2D electrophoresis, Western blot, and ELISA.

Figure 2.
Figure 2.

PRX-1 is expressed and released by the luminal part of AAA thrombus. A, Average spot volumes corresponding to luminal (L) (n=4) and abluminal (A) (n=4) samples are shown from the DeCyder software (*average ratio=1.78; P<0.05). B, Quantification of PRX-1 levels by ELISA measured in L and A layer supernatants (n=10, *P<0.001). C, Representative Western blot from L and A layer supernatants (n=10, *P<0.001). D, Immunodetection of PRX-1 in AAA thrombus (magnification, ×10). Inset 1 (magnification, ×20) shows erythrocyte accumulation with leukocyte (nucleated cells) in the luminal part of the thrombus. Inset 2 (magnification, ×20) shows erythrocytes and polynuclear cells positive for PRX-1 at the interface between the luminal an intermediary layers of the thrombus. Positivity is shown in green and nuclei in red. A.U. indicates arbitrary units.

PRX-1 Is Induced and Released by Oxidative Stress in RBCs

Because the main function of PRX-1 is the inactivation of hydrogen peroxide (H2O2), we analyzed H2O2 levels in AAA thrombus-conditioned media. Interestingly, H2O2 levels were also increased in the luminal layer versus the abluminal layer (17.2±5.4 versus 6.4±1.4 μmol/L, P<0.05). In addition, in vitro experiments with isolated RBCs stimulated with H2O2 (and lipopolysaccharide) were performed. We have shown that H2O2 and lipopolysaccharide induced PRX-1 translocation to the membrane and final release to the conditioned medium (Figure 3). These results suggest that PRX-1 is released as a response to prooxidant molecules present in the thrombus.

Figure 3.
Figure 3.

Western blot analysis of PRX-1 in RBCs. Representative Western blots were performed in RBCs isolated from healthy controls and stimulated with lipopolysaccharide (LPS) and H2O2 for 30 minutes at different concentrations. A, Total cell lysates. B, Supernatant obtained from cell culture. C, Membrane fractions.

Increased PRX-1 Levels in Serum of AAA Patients

This ex vivo approach offers the advantage of identifying proteins potentially released into the bloodstream that could serve as circulating biomarkers for AAA. We measured circulating PRX-1 levels in the serum of patients and controls by ELISA. Results showed that PRX-1 levels were significantly increased in patients with AAA relative to control subjects (14.9±3.5 versus 8±0.6 ng/mL, P<0.001, Figure 4A). Because AAA diameter is a surrogate marker of the growth rate, we studied the correlation between circulating PRX-1 levels and AAA diameter. Interestingly, a significant positive correlation between PRX-1 levels and AAA diameter was found (r=0.6, P<0.001, Figure 4B).

Figure 4.
Figure 4.

PRX-1 levels in AAA. A, Serum PRX-1 levels were measured from 33 control subjects and 83 patients with AAA (*P<0.001). B, PRX-1 levels correlate with AAA diameter (ρ=0.6; P<0.001, n=83). C and D, A positive correlation was observed between PRX-1 and PAP levels (ρ=0.4, P<0.01, n=83 patients) (D) and between PRX-1 and MPO levels (ρ=0.5, P<0.01, n=83 patients) (D).

Plasmin-antiplasmin (PAP) complexes and myeloperoxidase (MPO) levels are increased in patients with AAA.18,19 We confirmed these data in our patient population (data not shown). In addition, we have previously shown that both PAP and MPO levels are increased in the luminal part of the thrombus.18,19 Interestingly, PRX-1 positively correlated with both biomarkers of AAA in our patient population (PAP, r=0.4; MPO, r=0.55; P<0.05 for both; Figure 4C and 4D).

PRX-1 Circulating Levels Correlate With AAA Growth

To further extend the results obtained, we measured PRX-1 serum levels in a second cohort of 80 patients from the Viborg study, with a 5-year follow-up, allowing us to test the relevance of PRX-1 as a marker of AAA progression. Similar levels of circulating PRX-1 in small AAA patients (AAA size 3 to 5–5.5 cm) were obtained in both the Viborg and Spanish studies (Viborg=10.4±3.7 ng/mL versus small AAA Spanish=8.3±2.8 ng/mL). Interestingly, the correlation coefficient between PRX-1 levels and AAA growth rate was 0.3 (P=0.01, Figure 5A), persisting after adjustment for current smoking, body mass index, previous cardiovascular events, use of glucocorticoids, low-dose aspirin, β-blockers, angiotensin coverting enzyme inhibitors, and ankle brachial blood pressure index (Supplemental Table III). ROC curve analyses showed that PRX-1 levels were equally valid predictors of annual expansion rate as initial AAA size exceeding the mean annual growth, with optimal cutoff points with a sensitivity and specificity of 63% and 64%, respectively, for both (Figure 5B). By combining these 2 predictors (PRX-1 and AAA-size) by linear regression to predict annual expansion rate, the optimal validity increased by almost 10% to 72% sensitivity and 71% specificity. Moreover, comparison of the C-statistics showed that the 3 ROC curves differed significantly (χ2 test=9.11, P=0.01). Consequently, the combination of PRX-1 and size has significantly additive value in predicting growth compared with size alone.

Figure 5.
Figure 5.

PRX-1 and AAA growth in the Viborg cohort. A, PRX-1 levels were measured from an additional group of serum samples (Viborg cohort). PRX-1 correlates with AAA growth (ρ=0.3; P<0.05, n=80). B, ROC curve for predicting AAA expansion concerning PRX-1 levels and AAA size.

Discussion

Vascular diseases are currently among the most common pathologies, and despite outstanding scientific advances in recent years, the number of effective therapies and useful biomarkers is still very limited, although there is a continuous increase in costs associated with these diseases. Although several potential biomarkers of AAA have been proposed,2,3 it is essential to discover new biomarkers for early disease detection and risk stratification, which could predict clinical outcome. Moreover, identification of novel biomarkers could help decipher the biological mechanisms leading to progressive dilatation and finally rupture to develop new therapeutic approaches. Our study was performed on the thrombus conditioned medium as a potential source of biomarkers of AAA by a gel-based proteomic approach using DIGE platform. Among the proteins identified by MS, both novel and previously known protein biomarkers for AAA have been unveiled that are associated with some major AAA pathological processes, such as thrombosis and oxidative stress.

The formation of a luminal thrombus may be considered a compensatory mechanism in response to flow perturbations associated with AAA dilatation. The mural thrombus is continuously self-forming at its luminal pole and subjected to proteolysis at the interface with the residual media. Previous studies have shown that thrombus formation and accumulation of leukocytes may have an impact on the structural integrity and stability of the vessel wall and thereby increase the risk of aneurysm rupture.20 Proteins associated with thrombosis have been the biomarkers most commonly assessed in AAA. In this respect, levels of PAP complexes and d-dimers are elevated in AAA patients and correlate with disease progression.2,3 Similarly, elevated plasma fibrinogen concentrations predict a greater risk of thrombosis. Interestingly, fibrinogen levels are increased in AAA patients compared with controls, and positive correlations of AAA size, ILT, and fibrinogen concentration are observed.21 In the present work, among known biomarkers identified, we have shown that fibrinogen/fibrin fragments are abundantly released by the luminal part of the thrombus, in agreement with previous results of our group showing activation of the fibrinolytic system.19

Oxidative stress plays a key role in AAA pathophysiology.22 Although previous studies have mainly addressed the role of oxidative stress in AAA wall, the presence of a mural hemothrombus can also contribute to this process. The trapping of RBCs within ILT may lead to hemolysis and subsequent release of the prooxidant hemoglobin that, when oxidized, transfers heme to endothelium and lipoproteins, thereby enhancing susceptibility to oxidant-mediated injury. Heme potentiates cell cytotoxicity mediated by leukocytes and other sources of reactive oxygen species.23 Plasmatic hemopexin, haptoglobin, and albumin limit the hemoamplified oxidative damage to the vasculature. In the present work, a decrease in hemopexin and haptoglobin levels was observed in the luminal part of the thrombus, which could favor the prooxidant actions of hemoglobin.

However, oxidative stress is the result of imbalance between prooxidant and antioxidant molecules. In relation to antioxidant enzymes, superoxide dismutase, glutathione peroxidase, and thioredoxin expression levels are increased in AAA tissue.24,25 Thioredoxin, thioredoxin reductase, and NADPH together constitute a ubiquitous system that regulates cellular redox status. PRX-1 can interact and modulate NADPH activity by inactivating H2O2.26 In this respect, we observed that H2O2 levels were increased in the luminal layer versus the abluminal layer, similarly to the tendency observed for PRX-1. In addition, we have shown that H2O2 induced PRX-1 translocation to the membrane and final release to the conditioned medium in isolated RBCs. These results suggest that PRX-1 is released as a response to the prooxidant environment present in the ILT.

We hypothesized that the blood compartment could reflect what was observed in the arterial conditioned medium and thus that proteins potentially released into the circulation could serve as biomarkers for the pathology. We show here for the first time that PRX-1 levels are significantly increased in the serum of patients with AAA in relation to controls. Because AAA diameter is a surrogate marker of AAA growth rate and is the clinical parameter used in the management of AAA patients, we studied its potential correlation with PRX-1. We have observed that PRX-1 levels and AAA diameter show a significant positive correlation. Furthermore, a positive correlation among circulating PRX-1, PAP, and MPO levels has been shown, supporting the importance of ILT activities in AAA pathophysiology. Finally, PRX-1 also correlated with AAA growth in a second population with follow-up. Interestingly, by combining both AAA size with PRX-1 levels by linear regression to predict annual expansion rate above the interobserver variation of the measurements,16 the optimal validity increased almost by 10% up to 72% sensitivity and 71% specificity. The fact that PRX-1 correlates significantly with both AAA size and AAA growth rate in different populations (Spanish and Viborg studies), together with the observed comparable circulating levels in small AAA in the 2 populations, suggests the potential use of PRX-1 as a biomarker for AAA evolution.

On the other hand, despite the fact that PRX-1 levels could be increased in response to the oxidative stress present in AAA, the functional consequences of PRX-1 upregulation are not completely understood. In mammalian cells, high levels of peroxiredoxins are produced, which may account for 0.1% to 0.8% of soluble protein.27 PRX-1 is overexpressed in response to oxidative stress and has recently been involved in other mechanisms, such as shear stress.28 Several studies support an antioxidant and antiapoptotic role for PRX-1 upregulation. PRX-1 was initially described mainly as an antioxidant protein because of its ability to inactivate H2O2, ONOO2−, and other hydroperoxides. However, other cellular roles have been recently proposed for PRX-1, including the modulation of cytokine-induced H2O2 levels, which have been shown to mediate the signaling cascade that leads to cell proliferation, differentiation, and apoptosis,29 and proinflammatory actions.30 In this respect, PRX-1 has been shown to interact with other proteins and ligands, including hemo and macrophage migration inhibitor factor (MIF).27,31 MIF is upregulated in AAA32 and MIF serum levels have been correlated with annual AAA expansion rate and initial AAA size.33 Interestingly, we have observed a significant strong positive correlation between PRX-1 and MIF in the Viborg sample cohort (not shown). MIF, by modulating the redox status of PRX-1, has been suggested to modulate signaling pathways and glucocorticoid sensitivity.31 Likewise, we have observed a positive correlation between PRX-1 levels and glucocorticoid treatment.

In the present study, several proteins associated with key mechanisms involved in AAA pathogenesis have been identified by a non-hypothesis-driven proteomic approach. Among them, increased PRX-1 levels have been observed both in conditioned media and in serum from AAA patients. PRX-1 serum levels are associated with AAA size and growth rate, suggesting its possible use as a biomarker for AAA evolution. Additional prospective studies are needed to confirm these results. These results support a main pathological role of oxidative stress in AAA,22 as well as the potential usefulness of therapies aimed at enhancing antioxidant pathways to prevent AAA progression.34

Sources of Funding

This work was supported by the Fighting aneurysmal disease project (FP-7, HEALTH F2-2008-200647 to J-B.M., J.S.L., J.E.), Ministerio de Ciencia e Innovacion (SAF2010/21852 to J.L.M-V., SAF2007/63648 to J.E.), Fundacion Ramon Areces (to L.M.B-C.), CAM (S2006/GEN-0247 to J.E.), Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Redes RECAVA (RD06/0014/0035 to J.E.), PI10/00234 (to L.M.B-C.) and EUS2008-03565 (to J.E.) and Fundacion Pro CNIC (to J.A.L., E Calvo, E Camafeita).

Disclosures

None.

Acknowledgments

We thank Dr Cesar Aparicio for the collection of human samples.

  • Received August 9, 2010.
  • Accepted January 12, 2011.

References

  1. 1.↵
    1. Sakalihasan N,
    2. Limet R,
    3. Defawe OD
    . Abdominal aortic aneurysm. Lancet. 2005;365:1577–1589.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Urbonavicius S,
    2. Urbonaviciene G,
    3. Honore B,
    4. Henneberg EW,
    5. Vorum H,
    6. Lindholt JS
    . Potential circulating biomarkers for abdominal aortic aneurysm expansion and rupture: a systematic review. Eur J Vasc Endovasc Surg. 2008;36:273–280.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Golledge J,
    2. Tsao PS,
    3. Dalman RL,
    4. Norman PE
    . Circulating markers of abdominal aortic aneurysm presence and progression. Circulation. 2008;118:2382–2392.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Blanco-Colio LM,
    2. López JA,
    3. Martínez-Pinna Albar R,
    4. Egido J,
    5. Martín-Ventura JL
    . Vascular proteomics, a translational approach: from traditional to novel proteomic techniques. Expert Rev Proteomics. 2009;6:461–464.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Nordon I,
    2. Brar R,
    3. Hinchliffe R,
    4. Cockerill G,
    5. Loftus I,
    6. Thompson M
    . The role of proteomic research in vascular disease. J Vasc Surg. 2009;49:1602–16012.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Blanco-Colio LM,
    2. Martín-Ventura JL,
    3. Muñóz-García B,
    4. Orbe J,
    5. Páramo JA,
    6. Michel JB,
    7. Ortiz A,
    8. Meilhac O,
    9. Egido J
    . Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:916–922.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Martin-Ventura JL,
    2. Duran MC,
    3. Blanco-Colio LM,
    4. Meilhac O,
    5. Leclercq A,
    6. Michel JB,
    7. Jensen ON,
    8. Hernandez-Merida S,
    9. Tuñón J,
    10. Vivanco F,
    11. Egido J
    . Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation. 2004;110:2216–2219.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Fontaine V,
    2. Touat Z,
    3. Mtairag el M,
    4. Vranckx R,
    5. Louedec L,
    6. Houard X,
    7. Andreassian B,
    8. Sebbag U,
    9. Palombi T,
    10. Jacob MP,
    11. Meilhac O,
    12. Michel JB
    . Role of leukocyte elastase in preventing cellular re-colonization of the mural thrombus. Am J Pathol. 2004;164:2077–2087.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Caligiuri G,
    2. Rossignol P,
    3. Julia P,
    4. Groyer E,
    5. Mouradian D,
    6. Urbain D,
    7. Misra N,
    8. Ollivier V,
    9. Sapoval M,
    10. Boutouyrie P,
    11. Kaveri SV,
    12. Nicoletti A,
    13. Lafont A
    . Reduced immunoregulatory CD31+ T cells in patients with atherosclerotic abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2006;26:618–623.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Shevchenko A,
    2. Tomas H,
    3. Havlis J,
    4. Olsen JV,
    5. Mann M
    . In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc. 2006;1:2856–2860.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Schuerenberg M,
    2. Luebbert C,
    3. Eickhoff H,
    4. Kalkum M,
    5. Lehrach H,
    6. Nordhoff E
    . Prestructured MALDI-MS sample supports. Anal Chem. 2000;72:3436–3442.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Suckau D,
    2. Resemann A,
    3. Schuerenberg M,
    4. Hufnagel P,
    5. Franzen J,
    6. Holle A
    . A novel MALDI LIFT-TOF/TOF mass spectrometer for proteomics. Anal Bioanal Chem. 2003;376:952–965.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Perkins DN,
    2. Pappin DJ,
    3. Creasy DM,
    4. Cottrell JS
    . Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 1999;20:3551–3567.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Vega de Ceniga M,
    2. Esteban M,
    3. Quintana JM,
    4. Barba A,
    5. Estallo L,
    6. de la Fuente N,
    7. Viviens B,
    8. Martin-Ventura JL
    . Search for serum biomarkers associated with abdominal aortic aneurysm growth: a pilot study. Eur J Vasc Endovasc Surg. 2009;37:297–299.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Lindholt JS,
    2. Juul S,
    3. Fasting H,
    4. Henneberg EW
    . Screening for abdominal aortic aneurysms: single centre randomised controlled trial. BMJ. 2005;330:750.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Lindholt JS,
    2. Vammen S,
    3. Juul S,
    4. Henneberg EW,
    5. Fasting H
    . The validity of ultrasonographic scanning as screening method for abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 1999;17:472–475.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Neumann CA,
    2. Krause DS,
    3. Carman CV,
    4. Das S,
    5. Dubey DP,
    6. Abraham JL,
    7. Bronson RT,
    8. Fujiwara Y,
    9. Orkin SH,
    10. Van Etten RA
    . Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature. 2003;424:561–565.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Houard X,
    2. Touat Z,
    3. Ollivier V,
    4. Louedec L,
    5. Philippe M,
    6. Sebbag U,
    7. Meilhac O,
    8. Rossignol P,
    9. Michel JB
    . Mediators of neutrophil recruitment in human abdominal aortic aneurysms. Cardiovasc Res. 2009;82:532–541.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Houard X,
    2. Rouzet F,
    3. Touat Z,
    4. Philippe M,
    5. Dominguez M,
    6. Fontaine V,
    7. Sarda-Mantel L,
    8. Meulemans A,
    9. Le Guludec D,
    10. Meilhac O,
    11. Michel JB
    . Topology of the fibrinolytic system within the mural thrombus of human abdominal aortic aneurysms. J Pathol. 2007;212:20–28.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Kazi M,
    2. Thyberg J,
    3. Religa P,
    4. Roy J,
    5. Eriksson P,
    6. Hedin U,
    7. Swedenborg J
    . Influence of intraluminal thrombus on structural and cellular composition of abdominal aortic aneurysm wall. J Vasc Surg. 2003;38:1283–1292.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Al-Barjas HS,
    2. Ariëns R,
    3. Grant P,
    4. Scott JA
    . Raised plasma fibrinogen concentration in patients with abdominal aortic aneurysm. Angiology. 2006;57:607–614.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. McCormick ML,
    2. Gavrila D,
    3. Weintraub NL
    . Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2007;27:461–469.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Balla J,
    2. Vercellotti GM,
    3. Jeney V,
    4. Yachie A,
    5. Varga Z,
    6. Jacob HS,
    7. Eaton JW,
    8. Balla G
    . Heme, heme oxygenase, and ferritin: how the vascular endothelium survives (and dies) in an iron-rich environment. Antioxid Redox Signal. 2007;9:2119–2137.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Dubick MA,
    2. Keen CL,
    3. DiSilvestro RA,
    4. Eskelson CD,
    5. Ireton J,
    6. Hunter GC
    . Antioxidant enzyme activity in human abdominal aortic aneurysmal and occlusive disease. Proc Soc Exp Biol Med. 1999;220:39–45.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Martinez-Pinna R,
    2. Lindholt JS,
    3. Blanco-Colio LM,
    4. Dejouvencel T,
    5. Madrigal-Matute J,
    6. Ramos-Mozo P,
    7. Vega de Ceniga M,
    8. Michel JB,
    9. Egido J,
    10. Meilhac O,
    11. Martin-Ventura JL
    . Increased levels of thioredoxin in patients with abdominal aortic aneurysms (AAA): a potential link of oxidative stress with AAA evolution. Atherosclerosis. 2010;212:333–338.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Leavey PJ,
    2. Gonzalez-Aller C,
    3. Thurman G,
    4. Kleinberg M,
    5. Rinckel L,
    6. Ambruso DW,
    7. Freeman S,
    8. Kuypers FA,
    9. Ambruso DR
    . A 29-kDa protein associated with p67phox expresses both peroxiredoxin and phospholipase A2 activity and enhances superoxide anion production by a cell-free system of NADPH oxidase activity. J Biol Chem. 2002;277:45181–45187.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Wood ZA,
    2. Schroder E,
    3. Harris JR,
    4. Poole LB
    . Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci. 2003;28:32–40.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Mowbray AL,
    2. Kang DH,
    3. Rhee SG,
    4. Kang SW,
    5. Jo H
    . Laminar shear stress up-regulates peroxiredoxins (PRX) in endothelial cells: PRX 1 as a mechanosensitive antioxidant. J Biol Chem. 2008;83:1622–1627.
    OpenUrl
  29. 29.↵
    1. Wood ZA,
    2. Poole LB,
    3. Karplus PA
    . Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science. 2003;300:650–653.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Riddell JR,
    2. Wang XY,
    3. Minderman H,
    4. Gollnick SO
    . Peroxiredoxin 1 Stimulates Secretion of Proinflammatory Cytokines by Binding to TLR4. J Immunol. 2010;184:1022–1030.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Kudrin A,
    2. Ray D
    . Cunning factor: macrophage migration inhibitory factor as a redox-regulated target. Immunol Cell Biol. 2008;86:232–238.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Verschuren L,
    2. Lindeman JH,
    3. van Bockel JH,
    4. Abdul-Hussien H,
    5. Kooistra T,
    6. Kleemann R
    . Up-regulation and coexpression of MIF and matrix metalloproteinases in human abdominal aortic aneurysms. Antioxid Redox Signal. 2005;7:1195–1202.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Pan JH,
    2. Lindholt JS,
    3. Sukhova GK,
    4. Baugh JA,
    5. Henneberg EW,
    6. Bucala R,
    7. Donnelly SC,
    8. Libby P,
    9. Metz C,
    10. Shi GP
    . Macrophage migration inhibitory factor is associated with aneurysmal expansion. J Vasc Surg. 2003;37:628–635.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Grigoryants V,
    2. Hannawa KK,
    3. Pearce CG,
    4. Sinha I,
    5. Roelofs KJ,
    6. Ailawadi G,
    7. Deatrick KB,
    8. Woodrum DT,
    9. Cho BS,
    10. Henke PK,
    11. Stanley JC,
    12. Eagleton MJ,
    13. Upchurch GR
    . Tamoxifen up-regulates catalase production, inhibits vessel wall neutrophil infiltration, and attenuates development of experimental abdominal aortic aneurysms. J Vasc Surg. 2005;41:108–114.
    OpenUrlCrossRefPubMed
View Abstract

This Issue

Jump to

Article Tools

Share this Article

  • Email
  • Identification of Peroxiredoxin-1 as a Novel Biomarker of Abdominal Aortic Aneurysm
    Roxana Martinez-Pinna, Priscila Ramos-Mozo, Julio Madrigal-Matute, Luis M. Blanco-Colio, Juan A. Lopez, Enrique Calvo, Emilio Camafeita, Jes S. Lindholt, Olivier Meilhac, Sandrine Delbosc, Jean-Baptiste Michel, Melina Vega de Ceniga, Jesus Egido and Jose L. Martin-Ventura
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2011;31:935-943, originally published March 16, 2011
    https://doi.org/10.1161/ATVBAHA.110.214429
    Permalink:
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects